Y4B

allopregnanolone


Toggle HydrogenToggle Labels

Chemical Component Summary

Nameallopregnanolone
Synonyms3beta-hydroxy-5beta,10alpha,14beta,17alpha-pregnan-20-one; Brexanolone
Identifiers1-[(3~{R},5~{S},8~{R},9~{S},10~{S},13~{S},14~{S},17~{S})-10,13-dimethyl-3-oxidanyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1~{H}-cyclopenta[a]phenanthren-17-yl]ethanone
FormulaC21 H34 O2
Molecular Weight318.493
TypeNON-POLYMER
Isomeric SMILESCC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CC[C@H](C4)O)C)C
InChIInChI=1S/C21H34O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14-19,23H,4-12H2,1-3H3/t14-,15+,16-,17+,18-,19-,20-,21+/m0/s1
InChIKeyAURFZBICLPNKBZ-SYBPFIFISA-N

Chemical Details

Formal Charge0
Atom Count57
Chiral Atom Count8
Bond Count60
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB11859 
NameBrexanolone
Groups
  • investigational
  • approved
DescriptionAs of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females [F4066]. Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening condition [F4072]. Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083]. The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) in postpartum women susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone [F4063]. And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care [L5750].
Synonyms
  • Brexanolone
  • allopregnan-3α-ol-20-one
  • 3alpha-OH DHP
  • Allopregnanolone
Brand NamesZulresso
IndicationBrexanolone is a synthetic neuroactive steroid gamma-aminobutyric acid A (GABA(a)) receptor positive modulator indicated for the treatment of postpartum depression (PPD) in adult women [FDA Label][A176080, A176083, F4063, F4066, F4072].
Categories
  • Anesthetics
  • Anticonvulsants
  • Antidepressive Agents
  • Carbohydrates
  • Central Nervous System Agents
ATC-CodeN06AX29
CAS number516-54-1

Drug Targets

NameTarget SequencePharmacological ActionActions
GABA(A) ReceptorMRKSPGLSDCLWAWILLLSTLTGRSYGQPSLQDELKDNTTVFTRILDRLL...unknownpositive allosteric modulator
Aldose reductaseMASRLLLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQ...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 92786
ChEMBL CHEMBL207538
ChEBI CHEBI:50169